See Bull Run's current pages for Thyrocare Technologies and Dr Lal PathLabs. For another direct diagnostic-chain comparison, see Metropolis Healthcare vs Dr Lal PathLabs and Bull Run's diagnostic-company analysis guide.

Q1 FY27 scorecard: Dr Lal has scale, Thyrocare has exceptional efficiency

The most surprising result is the margin

Thyrocare is known for affordability.

Normally, investors associate lower pricing with lower margins.

Thyrocare demonstrates why that assumption can fail when the operating architecture is designed around extreme scale efficiency.

Thyrocare earns very little revenue per individual test

Its Q1 pathology operating metrics show approximately:

• ₹39.8 revenue per test;
• 10.2 tests per patient;
• ₹404 revenue per patient.

These are extraordinarily low-ticket economics compared with premium consumer-facing diagnostics.

Dr Lal generated ₹968 revenue per patient

Dr Lal's revenue per patient increased approximately 10% year on year.

That is more than twice Thyrocare's disclosed pathology revenue per patient.

Yet the EBITDA margins are very similar.

This is the key insight.

Low realization can work if cost per test is even lower

Thyrocare's model reduces unit costs through:

• large centralized processing;
• automation;
• high machine utilisation;
• dense sample logistics;
• franchisee-led customer acquisition;
• institutional partnerships;
• standardized test processing;
• limited dependence on expensive owned retail centres.

The business does not need ₹900-plus revenue per patient to create a 30%-plus EBITDA margin.

Its channel mix explains much of the model

This is fundamentally different from a premium consumer-led diagnostic network.

The franchise model transfers part of the retail infrastructure burden

Franchise partners include:

• local collection centres;
• smaller laboratories;
• nursing homes;
• hospitals.

Thyrocare processes samples while partners handle much of the local customer interface.

This creates an asset-light form of geographic expansion.

Thyrocare had 11,730 active franchisees

That was up from approximately 9,551 a year earlier.

The company added nearly 900 active franchisees during Q1 alone—the highest quarterly addition in roughly three years.

Its five-year active-franchise count has more than tripled.

Dr Lal's network is built differently

At FY26 year-end, Dr Lal reported approximately:

• 312 clinical laboratories;
• 7,727 Patient Service Centres;
• 13,935 pick-up points.

That infrastructure creates much more direct brand presence.

Dr Lal's network can support premium service and turnaround

A dense branded network improves:

• home-collection routes;
• customer convenience;
• doctor familiarity;
• turnaround times;
• consumer trust;
• regional brand dominance.

The trade-off is that consumer-facing infrastructure has costs.

Thyrocare has only 44 laboratories—and that is deliberate

The Q1 network included:

• two central processing laboratories;
• two zonal processing laboratories;
• seven hybrid labs;
• 22 regional processing laboratories;
• six satellite processing laboratories;
• four acquired labs;
• one international lab in Tanzania.

The philosophy is to put large test volume through relatively few high-throughput processing locations.

97% of Thyrocare samples are processed at NABL labs

The company's quality model has evolved alongside scale.

It reports:

• 97% of samples processed in NABL-accredited labs;
• approximately 3.37-hour lab turnaround time;
• 3.1 complaints per million tests;
• more than 100 pathologists;
• 1,375-plus test menu offerings.

Low cost therefore does not mean a minimal testing menu.

Thyrocare conducted 55.2 million Q1 tests

Reported test volume increased approximately 28%.

Patient volume increased 17% to 5.4 million.

The company revised its test-counting definition from Q1 FY27 to exclude calculated parameters and restated historical comparatives.

That methodology change matters

The companies report different units.

A sample can generate multiple tests.

A profile can contain multiple analytes.

Thyrocare itself changed its definition this year.

Patient volume and revenue are therefore safer cross-company measures.

On patients, Dr Lal is clearly larger

Dr Lal handled approximately 8.2 million patients.

Thyrocare handled approximately 5.4 million.

Dr Lal therefore served about 2.8 million more patients during the quarter.

Dr Lal patient growth was 8.2%

Thyrocare patient growth was approximately 17%.

Thyrocare is therefore expanding the number of patients at roughly twice Dr Lal's current percentage rate.

The starting base is smaller.

Dr Lal still grew revenue faster than patient volume

Revenue increased 19.1%.

Patients increased 8.2%.

Revenue per patient increased 10% to ₹968.

The improvement came from a combination of:

• test mix;
• geographic mix;
• more tests per patient;
• CGHS/ECHS realization changes.

This gives Dr Lal a second growth lever beyond volume

If patient count grows at high single digits while revenue per patient grows mid-to-high single digits, revenue can compound in the mid-teens.

That is exactly the business model management is currently targeting.

Thyrocare's growth is more volume-intensive

Standalone pathology revenue increased 26.1%.

Franchise revenue grew 27%.

Partnership revenue grew 26%.

D2C grew 17%.

The company is expanding reach while retaining its value-pricing proposition.

Standalone pathology is the cleanest Thyrocare engine

The pathology margin is higher than consolidated margin

Consolidated Thyrocare includes radiology operations.

Radiology generated only approximately ₹13.5 crore of revenue and ₹2.65 crore EBITDA.

Its EBITDA margin was approximately 19.6%.

This pulls the consolidated margin below pure pathology.

Thyrocare is actively pruning low-return radiology assets

Radiology revenue declined 4% because the company exited unprofitable centres.

Yet radiology EBITDA increased 23%.

PAT increased sharply because depreciation fell after centre closures.

This is a useful capital-allocation signal.

Growth without profitable density is not the objective

Diagnostics chains can destroy value by opening locations merely to increase footprint.

The right question is whether every centre, route and laboratory increases:

• samples per machine;
• revenue per employee;
• EBITDA per collection route;
• return on invested capital.

Thyrocare's restructuring suggests management is willing to remove underproductive assets.

Dr Lal's biggest advantage is absolute financial capacity

Dr Lal can fund acquisitions without meaningful leverage

Q1 developments included investments in:

• Sunshine Healthcare in Ghana;
• Neuome Technologies;
• new laboratories;
• radiology centres;
• technology and advanced testing.

The company can pursue these opportunities while maintaining a net-cash balance sheet.

Thyrocare is essentially debt-free too

Bull Run's standardized debt-to-equity is approximately zero for both businesses.

That is attractive because diagnostics should not require large structural leverage once a mature processing network has been built.

ROCE is where Thyrocare's architecture becomes most visible

Thyrocare converts less capital into high margins

A 35%-plus ROCE is extremely strong for a healthcare-services business.

The franchise and processing-hub architecture avoids tying up large amounts of capital in every neighbourhood.

This creates a powerful relationship:

low customer price + low operating cost + low capital intensity = high return on capital.

Dr Lal produces far more absolute free cash flow

Its five-year cumulative free cash flow is approximately three times Thyrocare's.

That is unsurprising because the business is much larger.

The key distinction is between:

• absolute cash generation;
• cash generation relative to capital employed.

Dr Lal wins the first.

Thyrocare currently wins the second.

The market values Dr Lal at 3.4 times Thyrocare

Yet Q1 PAT also differs by almost exactly the same ratio

Dr Lal generated ₹170 crore PAT.

Thyrocare generated ₹51.3 crore.

The ratio is approximately 3.3x.

Market capitalisation differs by approximately 3.4x.

This is why their P/E multiples are relatively close despite enormous absolute scale differences.

Thyrocare is cheaper on earnings

Bull Run P/E is approximately 47.8x.

Dr Lal trades around 53.3x.

Thyrocare therefore has:

• faster current revenue growth;
• slightly higher EBITDA margin;
• higher ROCE;
• lower P/E.

That is an unusually strong combination.

Why does Dr Lal still deserve a premium?

Because investors receive:

• larger patient scale;
• stronger consumer brand equity;
• far larger geographic collection infrastructure;
• ₹1,693 crore cash;
• advanced test capability;
• stronger absolute free cash flow;
• greater acquisition capacity.

The premium pays for lower business-scale risk.

Thyrocare's price-to-book is actually higher

Thyrocare trades around 14.4 times book value.

Dr Lal trades around 11.5 times.

This is not contradictory.

Thyrocare's higher ROE means every rupee of its current book equity generates more profit.

A capital-light business can rationally trade at a high book multiple.

Corporate actions make one-year share returns misleading

Historical price fields spanning those dates must be adjusted before calculating returns.

Bull Run therefore does not use the database's unadjusted one-year-return or historical 52-week-high fields to decide this comparison.

What must Thyrocare prove?

• Patient growth should remain in the mid-teens or better.
• Franchise additions must translate into revenue rather than merely footprint.
• Pathology EBITDA margin should remain above 30%.
• Specialty diagnostics must raise value per patient without damaging affordability.
• Radiology restructuring should improve consolidated returns.
• Advanced genomics and biomarkers need profitable adoption.
• High ROCE should survive network expansion.

What must Dr Lal PathLabs prove?

• Mid-teens revenue growth should remain sustainable after CGHS/ECHS realization benefits normalize.
• 31% Q1 EBITDA margin should prove durable.
• Patient growth should accelerate or remain healthy.
• South and West India expansion must produce attractive network density.
• International acquisitions should not dilute returns.
• ₹1,693 crore cash needs productive deployment.
• ROCE should remain comfortably above the cost of capital.

What could make Thyrocare outperform Dr Lal?

Its smaller base gives it greater percentage-growth potential.

If franchise growth, institutional partnerships and specialty diagnostics continue expanding while pathology margins remain around 33%, earnings can compound rapidly without enormous capital expenditure.

What could make Dr Lal outperform Thyrocare?

Dr Lal already possesses a national consumer brand and a much larger patient funnel.

If revenue per patient continues increasing while patient volumes grow high single digits or better, a 30%-plus EBITDA margin can translate into very large absolute cash flows.

Which company is larger?

Dr Lal PathLabs by a wide margin.

Revenue is roughly 3.3 times Thyrocare's and market capitalisation around 3.4 times larger.

Which is growing faster?

Thyrocare in Q1 FY27.

Consolidated revenue grew 24.3% versus Dr Lal at 19.1%.

Which has higher EBITDA margin?

Thyrocare, narrowly.

32.2% consolidated and 33.5% for standalone pathology versus Dr Lal at 31.0%.

Which has more patients?

Dr Lal PathLabs.

Approximately 8.2 million versus Thyrocare at 5.4 million.

Which has higher revenue per patient?

Dr Lal PathLabs.

Approximately ₹968 versus Thyrocare pathology at roughly ₹404.

The difference reflects very different channel and test-mix economics.

Which has higher ROCE?

Thyrocare.

Approximately 35.5% versus Dr Lal at 27.6% under Bull Run's standardized calculation.

Which stock is cheaper?

Thyrocare on trailing earnings.

Approximately 47.8x P/E versus Dr Lal at 53.3x.

Dr Lal trades at the lower price-to-book multiple.

Which is better: Thyrocare or Dr Lal PathLabs?

Dr Lal PathLabs currently has the stronger scale-and-franchise profile. It serves more patients, owns the larger physical diagnostics network, generates roughly three times Thyrocare's profit, holds ₹1,693 crore of cash and has a much greater absolute free-cash-flow base.

Thyrocare currently has the stronger operating-efficiency profile. Revenue is growing faster, consolidated EBITDA margin is slightly higher, pathology margins exceed 33%, ROCE is above 35% and the stock trades at the lower trailing P/E.

The comparison overturns the simplistic idea that premium diagnostics necessarily earns better returns.

Thyrocare charges dramatically less per patient but compensates through volume density, franchise economics and centralized processing.

Dr Lal earns far more per patient and uses its consumer brand and dense network to generate much larger absolute profit.

At September 2026 valuations, Thyrocare offers the stronger current combination of growth, margin, ROCE and P/E. Dr Lal remains the stronger lower-scale-risk franchise because of its patient base, cash balance and national network. Thyrocare becomes the more compelling compounder if it can preserve 30%-plus margins while moving from routine low-cost testing into higher-value specialty diagnostics.

Frequently asked questions